We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+6.61%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$216M
AUM Growth
-$2.51M
Cap. Flow
-$7.44M
Cap. Flow %
-3.45%
Top 10 Hldgs %
35.07%
Holding
172
New
38
Increased
33
Reduced
47
Closed
40

Top Buys

Rank Stock Value
1
AMED
Amedisys
AMED
+$3.63M
2
CPRI icon
Capri Holdings
CPRI
+$3.52M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$3.22M
4
SPLK
Splunk Inc
SPLK
+$3.13M
5
GPCR icon
Structure Therapeutics
GPCR
+$2.41M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.49M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.86M
3
BKI
Black Knight, Inc. Common Stock
BKI
+$3.59M
4
MMP
Magellan Midstream Partners, L.P.
MMP
+$3.49M
5
AJRD
Aerojet Rocketdyne Holdings
AJRD
+$3.38M

Sector Composition

Rank Sector Weight
1 Healthcare 46.09%
2 Technology 13.85%
3 Consumer Discretionary 6.89%
4 Financials 3.51%
5 Communication Services 3.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
26
Ionis Pharmaceuticals
IONS
$9.35B
$2.2M 1.02%
+48,520
New +$2M
GOOG icon
27
Alphabet (Google) Class C
GOOG
$4.23T
$2.19M 1.02%
16,636
-5,400
-25% -$702K
CRM icon
28
Salesforce
CRM
$161B
$2.12M 0.98%
10,479
-3,600
-26% -$778K
IMCR icon
29
Immunocore
IMCR
$1.75B
$2.07M 0.96%
39,804
-4,290
-10% -$254K
INSM icon
30
Insmed
INSM
$29.2B
$2.02M 0.93%
+80,000
New +$1.83M
V icon
31
Visa
V
$679B
$2.01M 0.93%
8,727
+600
+7% +$144K
RPTX
32
DELISTED
Repare Therapeutics
RPTX
$2M 0.92%
165,173
– –
DVAX
33
DELISTED
Dynavax Technologies
DVAX
$1.96M 0.91%
+133,000
New +$1.87M
IMRX icon
34
Immuneering
IMRX
$310M
$1.95M 0.9%
254,513
+1,403
+0.6% +$12.9K
XPO icon
35
XPO
XPO
$23.6B
$1.95M 0.9%
26,180
+5,900
+29% +$407K
COGT icon
36
Cogent Biosciences
COGT
$6.68B
$1.94M 0.9%
198,587
-17,543
-8% -$208K
MU icon
37
Micron Technology
MU
$962B
$1.92M 0.89%
+28,200
New +$1.89M
BCYC
38
Bicycle Therapeutics
BCYC
$290M
$1.86M 0.86%
92,434
– –
ELVN icon
39
Enliven Therapeutics
ELVN
$4.29B
$1.7M 0.79%
124,587
+3,514
+3% +$59.2K
XOMA
40
DELISTED
Xoma
XOMA
$1.68M 0.78%
118,899
– –
VRDN icon
41
Viridian Therapeutics
VRDN
$2.7B
$1.61M 0.74%
104,756
-4,009
-4% -$76.5K
KRTX
42
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$1.53M 0.71%
9,071
– –
MA icon
43
Mastercard
MA
$494B
$1.48M 0.69%
3,747
-500
-12% -$201K
X
44
DELISTED
US Steel
X
$1.39M 0.64%
+42,900
New +$1.2M
FCNCA icon
45
First Citizens BancShares
FCNCA
$25.3B
$1.33M 0.61%
961
+300
+45% +$412K
RIG icon
46
Transocean
RIG
$6.52B
$1.3M 0.6%
158,425
+56,100
+55% +$458K
TEVA icon
47
Teva Pharmaceuticals
TEVA
$42.5B
$1.27M 0.59%
+124,300
New +$1.16M
META icon
48
Meta Platforms (Facebook)
META
$1.54T
$1.26M 0.58%
4,190
-1,700
-29% -$512K
FISV
49
Fiserv Inc
FISV
$28.1B
$1.24M 0.57%
10,953
+3,400
+45% +$419K
XENE icon
50
Xenon Pharmaceuticals
XENE
$6.19B
$1.2M 0.56%
35,255
+17,680
+101% +$661K
1
2
3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $361M AUM 38.29% 1-Year Est. Return

HighVista Strategies's Q3 2023 Portfolio in Review

As of Q3 2023, HighVista Strategies held 172 positions worth $216M, down 1.1% from $219M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

HighVista Strategies withdrew a net $7.44M in Q3 2023, closing 40 positions and reducing 47 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $5.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 47% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, HighVista Strategies opened a new position in Amedisys worth $3.67M.

  • HighVista Strategies's largest Q3 2023 buy was Amedisys: 39,250 shares worth $3.67M.
  • HighVista Strategies added most to Merus in Q3 2023, an estimated $2.15M increase.
  • HighVista Strategies's biggest Q3 2023 reduction was MoonLake Immunotherapeutics, cutting an estimated $3.86M.
  • HighVista Strategies fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $5.49M.
  • HighVista Strategies's ten largest holdings make up 35% of its $216M portfolio in Q3 2023.
  • HighVista Strategies opened 38 new positions and closed 40 in Q3 2023.
  • HighVista Strategies's portfolio value fell 1.1% quarter-over-quarter to $216M.

Based on HighVista Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.